Monoclonal antibody (mAb) manufacturing must continually improve to keep up with increasing demands. To do this, biomanufacturers can deploy machine learning tools to augment traditional process ...

Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region. The drugmaker mapped ...

I-Mab stock has surged in 2025 on strong early data for lead asset givastomig in gastric cancer, showing an 83% ORR. Givastomig's results outperformed approved therapies and competitors, fueling ...

I-Mab has pivoted to focus on givastomig for gastric cancer after divesting its original China portfolio and revamping leadership. Givastomig shows superior early efficacy versus rivals, with ...

South Africa’s Black woman-founded S.MAB Group appoints new CEO, keeping leadership in women’s hands. South Africa’s pioneering Black woman-founded S.MAB Group has appointed a new CEO, continuing its ...

Vivian Ott is a scientist in the Center for Cell Cultivation Techniques at the ZHAW Zurich University of Applied Sciences, led by Professor Ing. Regine Eibl, PhD. Her work focuses on the development, ...

I-Mab has solidified its pivot to givastomig by buying out the owner of an antibody used in the therapy. Maryland-based I-Mab kicked off the year by announcing that it was pausing work on the ...

I-Mab acquires Bridge Health, gaining upstream rights to CLDN18.2 antibody, reducing milestone payments for givastomig and eliminating royalties. I-Mab has announced its acquisition of Bridge Health ...

The 2025 MAB Awards, presented by the Michigan Association of Broadcasters, were announced Monday, Feb. 24. Awards were handed out in the following categories: Commercial & Network Television, ...